

# Nanomedicine & Healthcare

November 06-07, 2017 | New Orleans, USA

## NanoBindi: A clinical-outcome focused, patient-centric precision therapeutic development platform

**Arkesh Mehta**

OncoBindi Therapeutics, USA


A technology-driven clinical outcome focused, patient-centric precision therapeutic development platform is operationally efficient and enables rapid, parallel development of multiple products in the portfolio without additional cost burden. Functional fabric encapsulated drugs (single or combination), where clinical function interfaces are integrated in the functional fabric architecture. The preconfigured clinical function interfaces enable dynamic integration of active targeting, increased availability at the cancer cell, protection from host defense and on demand controlled release for the optimal efficacy of the drug regimen. The smart dynamically transformative, clinical-outcome focused platform for the development of precision therapeutics has a small foot-print, is globally scalable and

regulatory agency compliant. In this way, the platform allows biopharmaceutical companies to develop a sustainable product portfolio in a collaborative ecosystem.

### Speaker Biography

Arkesh Mehta is a lifelong Entrepreneur with experience up and down the biopharmaceutical spectrum, since his first startup more than 15 years ago. He has co-founded and/or served as CEO or Executive Chairman for a set of leading-edge biotechnology, molecular diagnostics and healthcare IT companies. These companies had successful exits including BPI technologies, AT-GC BioPharm, Avanti NanoSciences and CBTEK. He is an Advisor and Board Member of several bio and healthcare startups. He has organized, Chaired and participated in number of international panels, including organizing the First NASDAQ panel on Bio-IT. He is a Member of Trustees for Sushita Group, a non-profit that fosters entrepreneurship.

e: [amehta@oncobindi.com](mailto:amehta@oncobindi.com)

 Notes: